BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37802870)

  • 1. [Zuogui Jiangtang Qinggan Formula improves glucolipid metabolism in type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease by regulating FoxO1/MTP/APOB signaling pathway].
    Xiang YX; Huang YL; Zhou M; Zou JJ; Liu X; Liu ZY; Xiao F; Yu R; Xiang Q
    Zhongguo Zhong Yao Za Zhi; 2023 Aug; 48(16):4438-4445. PubMed ID: 37802870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Zuogui Jiangtang Qinggan Prescription promotes recovery of intestinal mucosal barrier in mice with type 2 diabetes mellitus and nonalcoholic fatty liver disease by improving intestinal flora homeostasis].
    Zou JJ; Li H; Zhou M; Huang QQ; Wu YJ; Yu R
    Zhongguo Zhong Yao Za Zhi; 2023 Jan; 48(2):525-533. PubMed ID: 36725242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of Zuogui Jiangtang Qinggan Formula on lipid metabolism in db/db mouse model of type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease].
    Zhou M; Li L; Zou JJ; Liu X; Wu YJ; Xiang Q; Yu R
    Zhongguo Zhong Yao Za Zhi; 2024 Mar; 49(6):1587-1593. PubMed ID: 38621943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of diosgenin on mTOR/FASN/HIF-1α/VEGFA expression in rats with non-alcoholic fatty liver disease].
    Yin GL; Liang HY; Liang PP; Feng YN; Chen SW; Liu XY; Pan WC; Zhang FX
    Zhongguo Zhong Yao Za Zhi; 2023 Apr; 48(7):1760-1769. PubMed ID: 37282950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver Lipidomics Analysis Revealed the Protective mechanism of Zuogui Jiangtang Qinggan Formula in type 2 diabetes mellitus with non-alcoholic fatty liver disease.
    Zhou M; Liu X; Wu Y; Xiang Q; Yu R
    J Ethnopharmacol; 2024 Jul; 329():118160. PubMed ID: 38588985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and significance of fat mass and obesity associated gene and forkhead transcription factor O1 in non-alcoholic fatty liver disease.
    Zhang J; Li S; Li J; Han C; Wang Z; Li C; Wang X; Liu Z; Wen J; Zheng L
    Chin Med J (Engl); 2014; 127(21):3771-6. PubMed ID: 25382334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Gynostemma pentaphyllum saponins alleviate non-alcoholic fatty liver disease in rats by regulating intestinal flora and short-chain fatty acid metabolism].
    Zhong FW; Li GX; Zeng L
    Zhongguo Zhong Yao Za Zhi; 2022 May; 47(9):2500-2508. PubMed ID: 35531697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diosgenin alleviates NAFLD induced by a high-fat diet in rats via mTOR/SREBP-1c/HSP60/MCAD/SCAD signaling pathway].
    Chen SW; Yin GL; Song CY; Meng DC; Yu WF; Zhang X; Feng YN; Liang PP; Zhang FX
    Zhongguo Zhong Yao Za Zhi; 2023 Oct; 48(19):5304-5314. PubMed ID: 38114120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory effect of a Chinese herbal medicine formula on non-alcoholic fatty liver disease.
    Yang JM; Sun Y; Wang M; Zhang XL; Zhang SJ; Gao YS; Chen L; Wu MY; Zhou L; Zhou YM; Wang Y; Zheng FJ; Li YH
    World J Gastroenterol; 2019 Sep; 25(34):5105-5119. PubMed ID: 31558860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular mechanism of Fufang Zhenzhu Tiaozhi capsule in the treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease based on network pharmacology and validation in minipigs.
    Wang H; Tan H; Zhan W; Song L; Zhang D; Chen X; Lin Z; Wang W; Yang Y; Wang L; Bei W; Guo J
    J Ethnopharmacol; 2021 Jun; 274():114056. PubMed ID: 33771638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Purendan alleviates non-alcoholic fatty liver disease in aged type 2 diabetic rats via regulating mTOR/S6K1/SREBP-1c signaling pathway.
    Fan L; Niu H; Zhao L; Yao R; He X; Lu B; Pang Z
    Biomed Pharmacother; 2022 Apr; 148():112697. PubMed ID: 35176709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Octreotide on Hepatic Steatosis in Diet-Induced Obesity in Rats.
    Li M; Ye T; Wang XX; Li X; Qiang O; Yu T; Tang CW; Liu R
    PLoS One; 2016; 11(3):e0152085. PubMed ID: 27002331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zuogui-Jiangtang-Qinggan-Fang alleviates high-fat diet-induced type 2 diabetes mellitus with non-alcoholic fatty liver disease by modulating gut microbiome-metabolites-short chain fatty acid composition.
    Zou J; Xiang Q; Tan D; Shi L; Liu X; Wu Y; Yu R
    Biomed Pharmacother; 2023 Jan; 157():114002. PubMed ID: 36410120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JianPi-QingHua formula attenuates nonalcoholic fatty liver disease by regulating the AMPK/SIRT1/NF-κB pathway in high-fat-diet-fed C57BL/6 mice.
    Tian J; Cai M; Jin S; Chen Q; Xu J; Guo Q; Yan Z; Han X; Lu H
    Pharm Biol; 2023 Dec; 61(1):647-656. PubMed ID: 37038833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of celastrol on autophagy and endoplasmic reticulum stress-mediated apoptosis in a mouse model of nonalcoholic fatty liver disease].
    Tian T; Liao XC; Zhang M; Wu XM; Guo YT; Tan SY
    Zhonghua Gan Zang Bing Za Zhi; 2022 Jun; 30(6):656-662. PubMed ID: 36038329
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of Codonopsis Radix and Polygonati Rhizoma on the regulation of the IRS1/PI3K/AKT signaling pathway in type 2 diabetic mice.
    Mao YP; Song YM; Pan SW; Li N; Wang WX; Feng BB; Zhang JH
    Front Endocrinol (Lausanne); 2022; 13():1068555. PubMed ID: 36589810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic effects of globular adiponectin in diabetic rats with nonalcoholic fatty liver disease.
    Ma H; Cui F; Dong JJ; You GP; Yang XJ; Lu HD; Huang YL
    World J Gastroenterol; 2014 Oct; 20(40):14950-7. PubMed ID: 25356056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of metformin on the expression of SIRT1 and UCP2 in rat liver of type 2 diabetes mellitus and nonalcoholic fatty liver].
    Xu J; Li N; Wang J; Zhang C; Ding S; Jiao Y; Zhang J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Sep; 38(9):882-7. PubMed ID: 24071688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liraglutide Improves Non-Alcoholic Fatty Liver Disease In Diabetic Mice By Modulating Inflammatory Signaling Pathways.
    Luo Y; Yang P; Li Z; Luo Y; Shen J; Li R; Zheng H; Liang Y; Xia N
    Drug Des Devel Ther; 2019; 13():4065-4074. PubMed ID: 31819375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Berberine inhibits liver damage in rats with non-alcoholic fatty liver disease by regulating TLR4/MyD88/NF-κB pathway.
    Wang L; Jia Z; Wang B; Zhang B
    Turk J Gastroenterol; 2020 Dec; 31(12):902-909. PubMed ID: 33626003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.